Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Rank in Stocks #18279
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Share Price
$1.79
Last synced: 2026-09-02
Market Cap
$205.75M
Change (1 day)
3.18%
Change (1 year)
-61.61%
Country
US
Trade NovaBridge Biosciences (NBP)

Category

Number of shares outstanding for NovaBridge Biosciences (NBP)
Number of shares outstanding as of September 2026: 0
According to NovaBridge Biosciences latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of September 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for NovaBridge Biosciences (NBP) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH